公开(公告)号：US09624184B2

公开(公告)日：2017-04-18

申请号：US14781665

申请日：2014-04-03

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Masato Yoshikawa ,  Izumi Nomura ,  Yoshiteru Ito ,  Eiji Kimura ,  Haruhi Ando ,  Tomoaki Hasui ,  Toshiya Nishi

IPC: C07D413/10 ,  C07D491/08 ,  C07D413/12 ,  C07D413/14 ,  C07D263/32 ,  C07D413/04

CPC classification number: C07D263/32 ,  C07D413/04 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D491/08

Abstract: The present invention relates to a compound represented by the formula (I), which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. In the formula (I), each symbol is as defined in the specification.

公开(公告)号：US09296746B2

公开(公告)日：2016-03-29

申请号：US14435899

申请日：2013-10-15

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Masato Yoshikawa ,  Izumi Nomura ,  Yoshiteru Ito ,  Eiji Kimura ,  Tomoaki Hasui ,  Haruhi Ando ,  Hiromi Fukuda

IPC: C07D413/02 ,  C07D403/02 ,  A61K31/4245 ,  A61K31/416 ,  C07D471/04 ,  C07D519/00 ,  C07D413/04

CPC classification number: C07D471/04 ,  C07D413/04 ,  C07D519/00

Abstract: The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract translation: 本发明提供可用于预防或治疗神经变性疾病等的药剂的化合物或其盐。 本发明涉及由下式表示的化合物，其中每个符号如本说明书中所定义，或其盐。

公开(公告)号：US12152027B2

公开(公告)日：2024-11-26

申请号：US17296434

申请日：2019-11-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D487/04 ,  C07D471/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

公开(公告)号：US11897879B2

公开(公告)日：2024-02-13

申请号：US17528677

申请日：2021-11-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D471/04 ,  C07D487/04

CPC classification number: C07D471/04 ,  C07D487/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

公开(公告)号：US20210332045A1

公开(公告)日：2021-10-28

申请号：US17367171

申请日：2021-07-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Hiroshi Banno ,  Hidekazu Tokuhara ,  Toshio Tanaka ,  Yasuyoshi Arikawa ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D471/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

公开(公告)号：US20200247747A1

公开(公告)日：2020-08-06

申请号：US16777273

申请日：2020-01-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yasushi Hattori ,  Yuhei Miyanohana ,  Yuichi Kajita ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Norihito Tokunaga ,  Alexander Martin Pawliczek ,  Tsuneo Oda ,  Tohru Miyazaki ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Keisuke Imamura ,  Takahiro Sugimoto

IPC: C07D207/14 ,  C07D417/06 ,  C07D407/08

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10428023B2

公开(公告)日：2019-10-01

申请号：US16052967

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Kohei Takeuchi ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tohru Miyazaki ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D211/56 ,  A61P25/00 ,  C07D205/04 ,  C07D207/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14 ,  C07D405/06 ,  C07D211/36

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US11440883B2

公开(公告)日：2022-09-13

申请号：US16811426

申请日：2020-03-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Kohei Takeuchi ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tohru Miyazaki ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D211/56 ,  C07D211/36 ,  C07D405/06 ,  A61P25/26 ,  C07D409/10 ,  A61P25/00 ,  C07D205/04 ,  C07D207/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US11319286B2

公开(公告)日：2022-05-03

申请号：US16635408

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Kentaro Rikimaru ,  Koichiro Fukuda ,  Hiromichi Sugimoto ,  Takahiro Matsumoto ,  Yuichi Kajita ,  Satoshi Mikami ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Masaki Daini ,  Masaki Ogino ,  Kohei Takeuchi ,  Tohru Miyazaki ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D207/14 ,  C07D401/14 ,  C07D403/06 ,  A61P25/28

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US11230545B2

公开(公告)日：2022-01-25

申请号：US17367171

申请日：2021-07-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Hiroshi Banno ,  Hidekazu Tokuhara ,  Toshio Tanaka ,  Yasuyoshi Arikawa ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D471/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.